Is MapLight Therapeutics, Inc. Common Stock (MPLT) overvalued? · $1.24B cap
MapLight Therapeutics, Inc. Common Stock (MPLT) is a biotechnology company listed on NASDAQ.
This page asks whether MapLight Therapeutics, Inc. Common Stock (MPLT) looks expensive on cached numbers — not a short thesis.
No cached income statement for MPLT, so there is no earnings base to call rich or cheap.
MPLT currently screens at market cap $1.24B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MPLT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MPLT stock page for the full model, not this heading.
Not investment advice.